Protein Recognition in Signal Transduction
Protein Recognition in Signal Transduction
批准号:
10214557
负责人:
WENDELL A LIM
金额:
$34.52万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-01 至 2023-07-31
关键词:
AffinityAntibodiesAntigen TargetingAntigensB-LymphocytesBar CodesBiochemicalCell DensityCell LineCellsComplexDetectionDiseaseEngineeringEpidermal Growth Factor ReceptorGrantImmuneImmune signalingLeadLibrariesLogicMalignant NeoplasmsMemoryMethodsMusProteinsSeriesSignal PathwaySignal TransductionSolid NeoplasmT cell responseT-Cell ActivationT-Cell ReceptorT-LymphocyteTestingTherapeuticTherapeutic AgentsTissuesVariantXenograft procedureanti-cancerbasebehavioral responsecancer cellcancer immunotherapycell killingchimeric antigen receptorchimeric antigen receptor T cellscombinatorialdensitydesigneffective therapyengineered T cellsextracellularhuman tissueimprovedin vitro testingin vivoin vivo evaluationmembermouse modelneoplastic cellnext generationnovelnovel therapeuticsoverexpressionreceptorresponsescreening
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
T cells engineered to recognize and kill cancer cells via chimeric antigen receptors (CARs) have emerged as a
promising and potentially transformative therapeutic platform. CAR T cells have proven to be an extremely
effective therapy for certain B cell cancers. Nonetheless, many issues still remain in order to apply engineered
T cells to a broader range of cancers. First, current CAR T cells, are not able to discriminate between high and
low antigen expressing cells. Therefore, targeting antigens that are overexpressed in solid tumor cells (e.g.
Her2 or EGFR) can result in lethal off-target killing of bystander tissues expressing lower levels of the antigen.
Here we propose to attack this problem by using common biochemical mechanisms for cooperative recognition
(i.e. sigmoidal thresholds) to engineer new synthetic T cell receptors or circuits that can sense antigen density.
Second, we would ideally like to develop T cell receptor variants that, when activated, drive the cell to a more
persistent and effective state (e.g. Th1 or central memory state). To identify next-generation CARs that drive
particular T cell responses, we have developed a new strategy for constructing and screening a combinatorial
barcoded library of CARs that contain synthetic intracellular co-stimulatory signaling domains. We will screen
this library for CAR variants that improve T cell activation, proliferation, and differentiation. We will also use the
composite information from analyzing the library to identify critical signaling motifs most responsible for
directing T cell response trajectories towards specific paths. Our specific aims are:
Aim 1. Engineer synthetic T cell receptors and circuits that can discriminate cancer and bystander
cells based on differences in antigen density (using Her2 antigen as a primary testcase)
A. Engineer and test a series of cooperative low affinity but high valency CARs for Her2
B. Engineer and test cooperative two-step multi-receptor circuits for sharp threshold detection of Her2
C. Extend these density sensing strategies to sense EGFR density
Cells will be tested against cell lines expressing different antigen densities; They will be evaluated in vivo using
cell lines and PDX mouse models; crossreactivity will be tested using human tissue xenografts.
Aim 2. Build and screen combinatorial CAR libraries to identify synthetic T cell receptors with
optimized activation, proliferation and cell fate differentiation
A. Develop a novel method for assembling barcoded library of synthetic T cell receptors containing
combinations of linear immune signaling motifs (i.e. “synthetic co-stimulatory domains”)
B. Screen receptor libraries for receptors with specific optimized or novel response behaviors
We will evaluate the therapeutic function of new receptor candidates that emerge from these libraries;
Composite analysis will be used to better understand the dominant signaling motifs that direct particular types
responses. This project should yield improved next-generation therapeutic T cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Engineering synthetic immune cells with modular sentinel and therapeutic functions for T1D
-
批准号:10594512
-
项目类别:
-
资助金额:$83.16万
-
财政年份:2022
-
负责人:WENDELL A LIM
-
依托单位:
Ameliorating off-target toxicities of CAR T cells by engineering NOT gates
-
批准号:10657356
-
项目类别:
-
资助金额:$44.29万
-
财政年份:2022
-
负责人:WENDELL A LIM
-
依托单位:
Ameliorating off-target toxicities of CAR T cells by engineering NOT gates
-
批准号:10362126
-
项目类别:
-
资助金额:$45.11万
-
财政年份:2022
-
负责人:WENDELL A LIM
-
依托单位:
Engineering synthetic immune cells with modular sentinel and therapeutic functions for T1D
-
批准号:10436126
-
项目类别:
-
资助金额:$83.08万
-
财政年份:2022
-
负责人:WENDELL A LIM
-
依托单位:
Recognizing the tumor ecosystem: Integrating stromal and cancer antigen signals to achieve precision recognition of solid tumors by CAR T cells
-
批准号:10094815
-
项目类别:
-
资助金额:$56.32万
-
财政年份:2020
-
负责人:WENDELL A LIM
-
依托单位:
Recognizing the tumor ecosystem: Integrating stromal and cancer antigen signals to achieve precision recognition of solid tumors by CAR T cells
-
批准号:10559489
-
项目类别:
-
资助金额:$55.2万
-
财政年份:2020
-
负责人:WENDELL A LIM
-
依托单位:
Recognizing the tumor ecosystem: Integrating stromal and cancer antigen signals to achieve precision recognition of solid tumors by CAR T cells
-
批准号:10310406
-
项目类别:
-
资助金额:$14.7万
-
财政年份:2020
-
负责人:WENDELL A LIM
-
依托单位:
Engineering synthetic helper cells that autonomously deliver orthogonal IL-2 to selectively promote therapeutic T cell proliferation in tumors
-
批准号:10285941
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2019
-
负责人:WENDELL A LIM
-
依托单位:
UCSF Center for Synthetic Immunology: Tools to Reprogram the Immune System to Combat Cancer
-
批准号:10598367
-
项目类别:
-
资助金额:$5.93万
-
财政年份:2019
-
负责人:WENDELL A LIM
-
依托单位:
UCSF Center for Synthetic Immunology: Tools to Reprogram the Immune System to Combat Cancer
-
批准号:10598362
-
项目类别:
-
资助金额:$5.93万
-
财政年份:2019
-
负责人:WENDELL A LIM
-
依托单位:
Protein Recognition in Signal Transduction
-
批准号:10460232
-
项目类别:
-
资助金额:$33.83万
-
财政年份:2018
-
负责人:WENDELL A LIM
-
依托单位:
Redesigning the T cell: Using Synthetic Biology to Engineer Therapeutic Cells
-
批准号:9545542
-
项目类别:
-
资助金额:$66.13万
-
财政年份:2014
-
负责人:WENDELL A LIM
-
依托单位:
Redesigning the T cell: Using Synthetic Biology to Engineer Therapeutic Cells
-
批准号:9119791
-
项目类别:
-
资助金额:$66.11万
-
财政年份:2014
-
负责人:WENDELL A LIM
-
依托单位:
Redesigning the T cell: Using Synthetic Biology to Engineer Therapeutic Cells
-
批准号:9319242
-
项目类别:
-
资助金额:$66.13万
-
财政年份:2014
-
负责人:WENDELL A LIM
-
依托单位:
Redesigning the T cell: Using Synthetic Biology to Engineer Therapeutic Cells
-
批准号:8753520
-
项目类别:
-
资助金额:$68.03万
-
财政年份:2014
-
负责人:WENDELL A LIM
-
依托单位:
Harnessing CRISPR for Targeted and Inducible Epigenomic Reprogramming
-
批准号:9307796
-
项目类别:
-
资助金额:$51.35万
-
财政年份:2013
-
负责人:WENDELL A LIM
-
依托单位:
Harnessing CRISPR for Targeted and Inducible Epigenomic Reprogramming
-
批准号:8642014
-
项目类别:
-
资助金额:$50.9万
-
财政年份:2013
-
负责人:WENDELL A LIM
-
依托单位:
Harnessing CRISPR for Targeted and Inducible Epigenomic Reprogramming
-
批准号:9073782
-
项目类别:
-
资助金额:$11.98万
-
财政年份:2013
-
负责人:WENDELL A LIM
-
依托单位:
Harnessing CRISPR for Targeted and Inducible Epigenomic Reprogramming
-
批准号:8735919
-
项目类别:
-
资助金额:$51.21万
-
财政年份:2013
-
负责人:WENDELL A LIM
-
依托单位:
ELUCIDATING THE KINETIC MECHANISM OF SCAFFOLD-MEDIATED MAP KINASE SIGNALING
-
批准号:8363800
-
项目类别:
-
资助金额:$0.06万
-
财政年份:2011
-
负责人:WENDELL A LIM
-
依托单位:
海外基金